West Pharmaceutical Services Aktie 112491 / US9553061055
318.40
USD
6.65
USD
2.13%
20:57:21
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
West Pharmaceutical Services Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | West Pharmaceutical Services Inc. | 0.22 | 0.78 | USD |
| 2022 | West Pharmaceutical Services Inc. | 0.31 | 0.74 | USD |
| 2021 | West Pharmaceutical Services Inc. | 0.15 | 0.70 | USD |
| 2020 | West Pharmaceutical Services Inc. | 0.23 | 0.66 | USD |
| 2019 | West Pharmaceutical Services Inc. | 0.41 | 0.62 | USD |
| 2018 | West Pharmaceutical Services Inc. | 0.59 | 0.58 | USD |
| 2017 | West Pharmaceutical Services Inc. | 0.55 | 0.54 | USD |
| 2016 | West Pharmaceutical Services Inc. | 0.59 | 0.50 | USD |
| 2015 | West Pharmaceutical Services Inc. | 0.76 | 0.46 | USD |
| 2014 | West Pharmaceutical Services Inc. | 0.79 | 0.42 | USD |
Gewinn je Aktie- West Pharmaceutical Services
| 2.0 17 | 2.7 18 | 3.2 19 | 4.6 20 | 8.7 21 | 7.7 22 | 7.9 23 |
Umsatz je Aktie- West Pharmaceutical Services
| 21.1 17 | 22.8 18 | 24.5 19 | 28.3 20 | 37.1 21 | 38.1 22 | 39.2 23 |
KGV- West Pharmaceutical Services
| 49.6 17 | 35.7 18 | 46.9 19 | 62.0 20 | 54.1 21 | 30.4 22 | 44.7 23 |
West Pharmaceutical Services Inc.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 |
| Gewinn je Aktie unverwässert | 2.04 | 2.80 | 3.27 | 4.68 | 8.90 | 7.88 | 7.99 |
| Gewinn je Aktie verwässert | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 |
| Dividende pro Aktie | 0.54 | 0.58 | 0.62 | 0.66 | 0.70 | 0.74 | 0.78 |
| Gesamtdividendenausschüttung in Mio. | 39.10 | 42.10 | 45.10 | 48.10 | 51.10 | 54.10 | 57.00 |
West Pharmaceutical Services Inc.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 21.11 | 22.79 | 24.45 | 28.32 | 37.10 | 38.07 | 39.19 |
| KGV (Jahresendkurs, EPS unverwässert) | 49.63 | 35.73 | 46.90 | 62.03 | 54.07 | 30.45 | 44.68 |
| KGV (Jahresendkurs, EPS verwässert) | 49.63 | 35.73 | 46.90 | 62.03 | 54.07 | 30.45 | 44.68 |
| KGV (Jahresendkurs) | 49.63 | 35.73 | 46.90 | 62.03 | 54.07 | 30.45 | 44.68 |
| Dividendenrendite Jahresende in % | 0.55 | 0.59 | 0.41 | 0.23 | 0.15 | 0.31 | 0.22 |
| Eigenkapitalquote in % | 68.71 | 70.56 | 67.19 | 66.38 | 70.47 | 74.23 | 75.23 |
| Fremdkapitalquote in % | 31.29 | 29.44 | 32.81 | 33.62 | 29.53 | 25.77 | 24.77 |
West Pharmaceutical Services Inc.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 1’600.20 | 1’718.00 | 1’843.60 | 2’146.70 | 2’830.70 | 2’885.50 | 2’951.10 |
| Umsatzveränderung in % | 6.04 | 7.36 | 7.31 | 16.44 | 31.86 | 1.94 | 2.27 |
| Bruttoergebnis vom Umsatz | 514.50 | 546.30 | 608.80 | 767.90 | 1’173.40 | 1’138.90 | 1’132.70 |
| Bruttoergebnisveränderung in % | 2.69 | 6.18 | 11.44 | 26.13 | 52.81 | -2.94 | -0.54 |
| Operatives Ergebnis | 232.80 | 254.80 | 297.20 | 419.00 | 758.70 | 763.50 | 710.90 |
| Veränderung Operatives Ergebnis in % | 8.03 | 9.45 | 16.64 | 40.98 | 81.07 | 0.63 | -6.89 |
| Ergebnis vor Steuern | 222.40 | 240.70 | 291.80 | 401.30 | 748.90 | 679.90 | 698.00 |
| Veränderung Ergebnis vor Steuern in % | 17.18 | 8.23 | 21.23 | 37.53 | 86.62 | -9.21 | 2.66 |
| Ergebnis nach Steuer | 150.70 | 206.90 | 241.70 | 346.20 | 661.80 | 585.90 | 593.40 |
| Veränderung Ergebnis nach Steuer in % | 4.94 | 37.29 | 16.82 | 43.24 | 91.16 | -11.47 | 1.28 |
West Pharmaceutical Services Inc.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 583 | 583 | 768 | 939 | 978 | 932 | 949 |
| Langzeit Gesamtverbindlichk. pro Aktie | 4.11 | 4.03 | 5.76 | 5.89 | 5.18 | 5.57 | 3.76 |
| Eigenkapital | 1’280 | 1’396 | 1’573 | 1’855 | 2’335 | 2’685 | 2’881 |
| Veränderung Eigenkapital in % | 14.53 | 9.09 | 12.67 | 17.88 | 25.93 | 14.97 | 7.30 |
| Bilanzsumme | 1’863 | 1’979 | 2’341 | 2’794 | 3’314 | 3’617 | 3’830 |
| Veränderung Bilanzsumme in % | 8.51 | 6.23 | 18.32 | 19.32 | 18.61 | 9.14 | 5.88 |
West Pharmaceutical Services Inc.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 2.04 | 2.80 | 3.27 | 4.68 | 8.90 | 7.88 | 7.99 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 4.04 | 37.29 | 16.66 | 43.43 | 89.88 | -11.47 | 1.42 |
| Gewinn je Aktie (verwässert) | 1.99 | 2.74 | 3.21 | 4.57 | 8.67 | 7.73 | 7.88 |
| Veränderung Gewinn je Aktie (verwässert) in % | 4.09 | 38.02 | 16.82 | 42.48 | 89.91 | -10.88 | 1.95 |
| Anzahl Mitarbeiter | 7’500 | 7’700 | 8’200 | 9’200 | 10’065 | 10’700 | 10’600 |
| Veränderung Anzahl Mitarbeiter in % | 2.74 | 2.67 | 6.49 | 12.20 | 9.40 | 6.31 | -0.93 |
West Pharmaceutical Services Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| West Pharmaceutical Services Inc. | Quartalszahlen | 13.02.2025 |
| West Pharmaceutical Services Inc. | Quartalszahlen | 24.04.2025 |
| West Pharmaceutical Services Inc. | Quartalszahlen | 24.07.2025 |
| West Pharmaceutical Services Inc. | Quartalszahlen | 23.10.2025 |
West Pharmaceutical Services Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 24.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 25.07.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 25.04.2024 |
| Hauptversammlung | Annual General Meeting | 23.04.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 15.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 27.07.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Hauptversammlung | Annual General Meeting | 25.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 16.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 28.07.2022 |
| Hauptversammlung | Annual General Meeting | 24.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 17.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.40 |
| The Vanguard Group, Inc. | 12.43 |
| Vanguard Group, Inc. (Subfiler) | 11.96 |
| State Street Corp. | 4.44 |
| Artisan Partners Holdings LP | 4.23 |
| Walter Scott & Partners Ltd. | 3.81 |
| AllianceBernstein LP | 3.59 |
| BlackRock Fund Advisors | 3.44 |
| APG Asset Management NV | 3.19 |
| Vanguard Total Stock Market ETF | 3.18 |
| Franklin Advisers, Inc. | 3.11 |
| Brown Advisory LLC | 3.03 |
| Stichting Pensioenfonds ABP (Global Equity Portfolio) | 2.95 |
| Vanguard 500 Index Fund | 2.62 |
| Geode Capital Management LLC | 2.40 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 8’200 | 9’200 | 10’065 | 10’700 | 10’600 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.22 | 0.23 | 0.28 | 0.27 | 0.28 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1’059 | 1’374 | 1’742 | 1’920 | 1’936 |
| Summe Anlagevermögen | 1’283 | 1’420 | 1’572 | 1’697 | 1’893 |
| Summe Aktiva | 2’341 | 2’794 | 3’314 | 3’617 | 3’830 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 329 | 326 | 325 | 318 | 309 |
| Summe Fremdkapital | 768 | 939 | 978 | 932 | 949 |
| Summe Eigenkapital | 1’573 | 1’855 | 2’335 | 2’685 | 2’881 |
| Summe Passiva | 2’341 | 2’794 | 3’314 | 3’617 | 3’830 |
Adresse
| 530 Herman O. West Drive, 19341-0645 Exton | |
| Telefon | +1 (610) 594-2900 |
| Fax | +1 (800) 345-9800 |
| URL | http://www.westpharma.com |
Management
|
Annette F. Favorite
Chief Human Resources Officer & Senior VP |
|
Bernard J. Birkett
Chief Financial Officer |
|
Chad R. Winters
Chief Accounting Officer, VP & Controller |
|
Chris Ryan
Senior Vice President-Containment & Glass Systems |
|
Cindy Reiss-Clark
Chief Commercial Officer & Senior Vice President |
|
Deborah L. V. Keller
Independent Director |
|
Donald A. McMillan
Vice President-Enterprise Business Systems |
|
Douglas A. Michels
Independent Director |
|
Eric Mark Green
Chairman, President & Chief Executive Officer |
|
Kathy dePadua
Chief Quality Officer & Vice President |
|
Kimberly Banks MacKay
Secretary, General Counsel & Senior Vice President |
|
Mark A. Buthman
Independent Director |
|
Molly E. Joseph
Independent Director |
|
Myla P. Lai-Goldman
Independent Director |
|
Paolo Pucci
Lead Independent Director |
|
Quintin John Lai
Vice President-Strategy & Investor Relations |
|
Robert F. Friel
Independent Director |
|
Robert Segura
Vice President-Corporate Development |
|
Rudy Poussot
Senior VP-Strategy & Corporate Development |
|
Silji Abraham
Chief Technology Officer & Senior Vice President |
|
Stephen H. Lockhart
Independent Director |
|
Thomas W. Hofmann
Independent Director |
|
William F. Feehery
Independent Director |